• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

    11/4/24 7:19:49 AM ET
    $SERA
    Medical Specialities
    Health Care
    Get the next $SERA alert in real time by email
    SC 13G/A 1 zk2432210.htm SC 13G/A


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
    Under the Securities Exchange Act of 1934

    Sera Prognostics, Inc.

    (Name of Issuer)
     
    Class A Common Stock, Par Value $0.0001 per Share
    (Title of Class of Securities)
     
    81749D107

    (CUSIP Number)
    September 30, 2024

    (Date of Event which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ☐ Rule 13d-1(b)
     
    ☐ Rule 13d-1(c)
     
    ☒ Rule 13d-1(d)
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
     


    CUSIP No.
      
    81749D107
     
    1.
    Names of Reporting Persons
     
    aMoon Growth Fund Limited Partnership
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Cayman Islands 
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power

    1,911,332
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    1,911,332
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    1,911,332
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    5.73%
    12.
    Type of Reporting Person (See Instructions)
     
    PN 

    Page 2 of 9 Pages


    CUSIP No.
      
    81749D107
     
    1.
    Names of Reporting Persons
     
    aMoon Growth Fund G.P. Limited Partnership
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power

    1,911,332
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    1,911,332
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    1,911,332
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    5.73%
    12.
    Type of Reporting Person (See Instructions)
     
    PN 

    Page 3 of 9 Pages


    CUSIP No.
      
    81749D107
     
    1.
    Names of Reporting Persons
     
    aMoon General Partner Ltd.
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power

    1,911,332
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    1,911,332
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    1,911,332
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    5.73%
    12.
    Type of Reporting Person (See Instructions)
     
    CO

    Page 4 of 9 Pages


    CUSIP No.
      
    81749D107
     
    1.
    Names of Reporting Persons
     
    Dr. Yair C. Schindel
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power

    1,911,332
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    1,911,332
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    1,911,332
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    5.73%
    12.
    Type of Reporting Person (See Instructions)
     
    IN
     
    Page 5 of 9 Pages


    Item1 (a)
    Name of Issuer
     

    Sera Prognostics, Inc. (the “Issuer”).

    Item 1(b)
    Address of Issuer’s Principal Executive Offices
     

    2749 East Parleys Way, Suite 200, Salt Lake City, Utah 84109

    Item 2(a)-(b)
    Name of Person Filing; Address of Principal Business Office or, if none, Residence
     

    1.
    aMoon Growth Fund Limited Partnership (“aMoon”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    2.
    aMoon Growth Fund G.P. Limited Partnership (“aMoon G.P.”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    3.
    aMoon General Partner Ltd. (“aMoon Ltd.”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    4.
    Dr. Yair C. Schindel (“Schindel”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     
    The foregoing persons are hereinafter collectively referred to as the “Reporting Persons”. 
     
    Item 2(c)
    Citizenship
     

    aMoon is a Cayman Islands exempted limited partnership; aMoon G.P. is an Israeli limited partnership; aMoon Ltd. is an Israeli company; and Schindel is an Israeli citizen.

    Item 2(d)
    Title of Class of Securities
     

    Class A Common Stock, par value $0.0001 per share

    Item2(e)
    CUSIP Number


    81749D107

    Item 3
    If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
     

    Not applicable.

    Item 4
    Ownership
     

    aMoon Growth Fund Limited Partnership


    (a)
    Amount beneficially owned:  1,911,332 shares of Class A Common Stock.

    All share percentage calculation are based on 33,353,847 shares of Class A Common Stock and Class B Common Stock outstanding as of June 30, 2024, as reported by the Issuer to the SEC on Form 424B5 on August 13, 2024.


    (b)
    Percent of Class: 5.73%

    Page 6 of 9 Pages




    (c)
    Number of shares as to which the  person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 1,911,332  shares of Class A Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 1,911,332  shares of Class A Common Stock

    aMoon Growth Fund G.P. Limited Partnership


    (a)
    Amount beneficially owned: 1,911,332 shares of Class A Common Stock.  aMoon G.P. is the sole general partner of aMoon.  By virtue of such relationship, aMoon G.P. may be deemed to have shared voting and investment power with respect to the shares of Class A Common Stock of the Issuer held by aMoon.

    All share percentage calculation are based on 33,353,847 shares of Class A Common Stock and Class B Common Stock outstanding as of June 30, 2024, as reported by the Issuer to the SEC on Form 424B5 on August 13, 2024.


    (b)
    Percent of Class: 5.73%


    (c)
    Number of shares as to which the  person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 1,911,332  shares of Class A Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 1,911,332  shares of Class A Common Stock

    aMoon General Partner Ltd.


    (a)
    Amount beneficially owned:  1,911,332 shares of Class A Common Stock.  aMoon Ltd. is the sole general partner of aMoon G.P.  By virtue of such relationships, aMoon Ltd. may be deemed to have shared voting and investment power with respect to the shares of Class A Common Stock of the Issuer held by aMoon.

    All share percentage calculation are based on 33,353,847 shares of Class A Common Stock and Class B Common Stock outstanding as of June 30, 2024, as reported by the Issuer to the SEC on Form 424B5 on August 13, 2024.


    (b)
    Percent of Class: 5.73%


    (c)
    Number of shares as to which the  person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 1,911,332  shares of Class A Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 1,911,332  shares of Class A Common Stock

    Dr. Yair C. Schindel


    (a)
    Amount beneficially owned:  1,911,332 shares of Class A Common Stock.  Schindel is the sole shareholder of aMoon Ltd. By virtue of such relationships, Schindel may be deemed to have shared voting and investment power with respect to the shares of Class A Common Stock of the Issuer held by aMoon. Schindel disclaims beneficial ownership of the shares of Class A Common Stock of the Issuer held by aMoon, aMoon G.P. and aMoon Ltd., except to the extent of his pecuniary interest therein, if any.

    Page 7 of 9 Pages


    All share percentage calculation are based on 33,353,847 shares of Class A Common Stock and Class B Common Stock outstanding as of June 30, 2024, as reported by the Issuer to the SEC on Form 424B5 on August 13, 2024.


    (b)
    Percent of Class: 5.73%


    (c)
    Number of shares as to which the  person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 1,911,332  shares of Class A Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 1,911,332  shares of Class A Common Stock

    Item 5
    Ownership of Five Percent or Less of a Class
     

    Not applicable.

    Item 6
    Ownership of More than Five Percent on Behalf of Another Person
     

    Not applicable.

    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
     

    Not applicable.

    Item 8
    Identification and Classification of Members of the Group
     

    Incorporated by reference to Items 2 and 4 of this Schedule 13G.

    Item 9
    Notice of Dissolution of Group
     

    Not applicable.

    Item 10
    Certification
     

    Not applicable.

    Page 8 of 9 Pages

     
    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 4, 2024

      AMOON GROWTH FUND LIMITED PARTNERSHIP
    BY: AMOON GROWTH FUND G.P. LIMITED PARTNERSHIP, ITS GENERAL PARTNER
    BY:  AMOON GENERAL PARTNER LTD., ITS GENERAL PARTNER
     
           

    By:
    /s/ Dr. Yair C. Schindel  
        Name: Dr. Yair C. Schindel  
       
    Title:   Director
     

     
    AMOON GROWTH FUND G.P. LIMITED PARTNERSHIP
    BY:  AMOON GENERAL PARTNER LTD., ITS GENERAL PARTNER
     
           

    By:
    /s/ Dr. Yair C. Schindel  
        Name: Dr. Yair C. Schindel  
       
    Title:   Director
     

     
    AMOON GENERAL PARTNER LTD.
     
           

    By:
    /s/ Dr. Yair C. Schindel  
        Name: Dr. Yair C. Schindel  
       
    Title:   Director
     

     
    DR. YAIR C. SCHINDEL
     
           

    By:
    /s/ Dr. Yair C. Schindel  

    Page 9 of 9 Pages
    Get the next $SERA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SERA

    DatePrice TargetRatingAnalyst
    3/30/2022$18.00 → $4.00Buy → Neutral
    Citigroup
    11/19/2021$19.00Outperform
    Oppenheimer
    10/15/2021Outperform
    Cowen
    8/9/2021Outperform
    William Blair
    8/9/2021Outperform
    Cowen
    8/9/2021$18.00Buy
    Citigroup
    More analyst ratings

    $SERA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mirza Mansoor Raza sold $259 worth of shares (106 units at $2.44), decreasing direct ownership by 0.24% to 43,672 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      5/9/25 7:18:31 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Chief Executive Officer Lindgardt Zhenya sold $22,951 worth of shares (9,406 units at $2.44), decreasing direct ownership by 1% to 867,251 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      5/9/25 7:18:14 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Chief Data Officer Kearney Paul sold $17,297 worth of shares (7,089 units at $2.44), decreasing direct ownership by 3% to 196,711 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      5/9/25 7:17:53 PM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    Financials

    Live finance-specific insights

    See more
    • SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

      SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights: Following release of full Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") study results meeting primary success criteria, Sera is elevating engagement with payors and plan administrat

      5/7/25 4:05:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2025 Financial Results on May 7, 2025

      SALT LAKE CITY, April 24, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2025 financial results on Wednesday, May 7, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

      4/24/25 8:30:00 AM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights: On January 6, 2025, the Society for Maternal Fetal Medicine ("SMFM") published an abstract reporting topline results for Sera's Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PR

      3/19/25 4:05:00 PM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    SEC Filings

    See more
    • SEC Form 144 filed by Sera Prognostics Inc.

      144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      5/9/25 7:20:09 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form 144 filed by Sera Prognostics Inc.

      144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      5/9/25 7:19:32 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)

      5/8/25 5:20:29 PM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sera Prognostics downgraded by Citigroup with a new price target

      Citigroup downgraded Sera Prognostics from Buy to Neutral and set a new price target of $4.00 from $18.00 previously

      3/30/22 7:52:32 AM ET
      $SERA
      Medical Specialities
      Health Care
    • Oppenheimer initiated coverage on Sera Prognostics with a new price target

      Oppenheimer initiated coverage of Sera Prognostics with a rating of Outperform and set a new price target of $19.00

      11/19/21 4:55:47 AM ET
      $SERA
      Medical Specialities
      Health Care
    • Cowen resumed coverage on Sera Prognostics

      Cowen resumed coverage of Sera Prognostics with a rating of Outperform

      10/15/21 7:31:16 AM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

      SALT LAKE CITY, May 29, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that members of the Sera team will participate in the following upcoming investor conferences: William Blair 45th Annual Growth Stock ConferenceDate: June 3 – 5, 20251X1 Meetings OnlyDoug Fisher, M.D., Strategic Advisor to Sera and former Chief Business Officer, will participate in meetings on Wednesday, June 4, 2025. Jefferies

      5/29/25 8:30:00 AM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCE

      SALT LAKE CITY , May 14, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the RBC Global Healthcare Conference on Wednesday, May 21, 2025, from 9:30 – 9:55 a.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss the company's latest achievements. A live webcast of the company's presentation as well as

      5/14/25 4:05:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER

      Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.

      5/8/25 4:40:00 PM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

      SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      11/14/24 5:46:12 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

      SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      11/4/24 7:19:49 AM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Sera Prognostics Inc.

      SC 13G - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      4/1/24 7:33:43 PM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    Leadership Updates

    Live Leadership Updates

    See more
    • SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER

      Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.

      5/8/25 4:40:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

      3/19/25 4:10:00 PM ET
      $EXAS
      $QTRX
      $SERA
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO

      SALT LAKE CITY, May 15, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the retirement of the Company's President and CEO, Gregory C. Critchfield, M.D., M.S. Dr. Critchfield is retiring after 12 years of dedicated and valuable service to the Company. Dr. Critchfield plans to step down from his executive role effective June 8, 2023, to pursue other activities. Zhenya Lindgardt, a member of the Company's Board of Directors, will succeed Dr. Critchfield, as Interim CEO & President. Kim Kamdar, Ph.D., a member of the

      5/15/23 5:15:00 PM ET
      $SERA
      Medical Specialities
      Health Care